The concept of angiogenesis and anti-angiogenesis is probably one of the most important advances in our assessment of physiopathological processes and also an example of progress in our understanding of physiological development. It is for this
reason that the decision was made nearly 4 years ago to devote one of the Institut Servier meetings to this topic, particularly as it covers the majority of medical disciplines and can be considered as what is nowadays known as a transversal theme.

Although the potential use of an anti-angiogenic treatment for cancer was ἀrst mentioned by Folkman nearly 37 years ago (1971), it is in the last 5 years that therapeutic trials in two opposing domains have multiplied:
––use of pro-angiogenic medications in ischemic disease, mainly critical lower-limb ischemia and coronary disease, with the as yet unconἀrmed hope of blocking the process of restenosis after angioplasty and/or stent implantation;
––use of anti-angiogenic therapies in the treatment of cancer, with three drugs currently available: bevacizumab (Avastin ®), sorafenib, imitinib). Particularly in metastatic renal cancer, the achievements are unquestionable, with successful albeit less spectacular results in colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma. Although the activity of anti-angiogenic agents in monotherapy is not to be discounted, it proves most interesting when coupled with chemotherapy.

The mechanism of angiogenesis is as follows: it functions just as well in disease situations as in healthy adults by awakening quiescent endothelial cells, thus promoting neovascularisation. An example is that of extended muscular exercise where local hypoxia, resulting from an increase in local oxygen consumption, is compensated by capillarogenesis.

Summary

Introduction
Pierre Godeau

Tribute to Roger Luccioni
Pierre Godeau

Molecular bases of physiological and pathological angiogenesis
Pierre Corvol

Angiogenesis and neurogenesis
Anne Eichmann

Postischemic angiogenesis: experimental aspects and therapeutic perspectives
Bernard Lévy, Jean-Sébastien Silvestre

Gene and cell therapy in peripheral arterial disease
Joseph Emmerich

Cell therapy in cardiac disease
Philippe Menasché

On the symbolism of angiogenesis and anti-angiogenesis
Janine Chanteur

Hypoxia and tumur progression: new therapeutic approaches
Jacques Pouysségur

An appraisal of anti-angiogenics in oncology
Olivier Rixe

Anti-angiogenesis and eye disease; age-related macular degeneration
José-Alain Sahel, Michel Paques

Tumur blood vessels: a major therapeutic target
Gérard Tobelem

Limitations and complications of anti-angiogenic treatments
Jean-Jacques Mourad

Organizers
Pr Pierre Corvol, Pr Pierre Godeau, Pr Roger Luccioni (†)
Authors
Pierre Godeau, Pierre Corvol, Anne Eichmann, Bernard Lévy, Jean-Sébastien Silvestre, Joseph Emmerich, Philippe Menasché, Janine Chanteur, Jacques Pouysségur, Olivier Rixe, José-Alain Sahel, Michel Pâques, Gérard Tobelem, Jean-Jacques Mourad
Organizers
Pr Pierre Corvol, Pr Pierre Godeau, Pr Roger Luccioni (†)
Authors
Pierre Godeau, Pierre Corvol, Anne Eichmann, Bernard Lévy, Jean-Sébastien Silvestre, Joseph Emmerich, Philippe Menasché, Janine Chanteur, Jacques Pouysségur, Olivier Rixe, José-Alain Sahel, Michel Pâques, Gérard Tobelem, Jean-Jacques Mourad
Category
Cardiovascular diseases
Publication type
Proceedings
Year
2008
Download the publication